<DOC>
	<DOCNO>NCT00776828</DOCNO>
	<brief_summary>Objectives : - To evaluate influence concomitant use cilostazol aspirin clopidogrel composite cardiovascular adverse outcome ( cardiac death , myocardial infarction , nonhemorrhagic stroke , target lesion revascularization ) drug-eluting stent implantation Study Design : Prospective , open label , two arm , randomize multicenter trial test superiority cilostazol group compare control group . Patients randomize accord use cilostazol Patient Enrollment : 960 patient enrol 5 center Korea Patient Follow-up : Clinical follow-up occur 1 , 3 6 month . Angiographic follow-up recommend patient 6 month index procedure . Primary Endpoint - Composite adverse cardiovascular/cerebrovascular outcome ( cardiac death , myocardial infarction , nonhemorrhagic stroke , target lesion revascularization ) within 6 month Secondary Endpoint - All cause death , stent thrombosis , component primary endpoint six month - PRU level measure discharge index procedure six month Safety Endpoint - Bleeding complication accord TIMI criterion - The incidence drug discontinuation - Heart rate</brief_summary>
	<brief_title>The Efficacy CILostazol ON Ischemic Complications After DES Implantation</brief_title>
	<detailed_description>Stratified randomization statin type ( rosuvastatin atorvastatin ) center perform</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Subject must leat 18 year age Subject able verbally confirm understandings risk , benefit treatment alternative cilostazol he/she his/her legally authorized representative provide write informed consent prior study related procedure . Subject must significant coronary artery stenosis ( &gt; 50 % visual estimate ) Subject must evidence myocardial ischemia ( e.g. , stable , unstable angina , recent infarction , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia . In subject coronary artery stenosis &gt; 75 % , evidence myocardial ischemia document . Coronary lesion must amenable percutaneous coronary revascularization drug elute stent . Subject undergoes primary percutaneous coronary intervention due acute ST elevation myocardial infarction Subject contraindication allergy antiplatelet agent ( aspirin , clopidogrel cilostazol ) Subject thrombocytopenia ( &lt; 120,000/uL ) Subject liver cirrhosis ( Child class B C ) Subject anticoagulation therapy Subject severe congestive heart failure ( left ventricular ejection fraction &lt; 30 % )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>cilostazol</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>statin</keyword>
	<keyword>drug-eluting stent</keyword>
</DOC>